VEGF 165 Protéine

N° du produit ABIN7275824

Détail du produit

Antigène: VEGF 165

Type de proteíne: Recombinant

Origine: Humain

Source: HEK-293 Cells

Séquence: Ala27-Arg191

Pureté: > 95% as determined by Tris-Bis PAGE,> 95% as determined by HPLC

Stérilité: 0.22 μm filtered

niveau d'endotoxine: Less than 1EU per μg by the LAL method.

Biological Activity Comment: Immobilized Human VEGF165 at 1μg/ml (100μl/well) on the plate. Dose response curve for Human VEGFR2, mFc Tag with the EC50 of 74.2ng/ml determined by ELISA. See testing image for detail.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 5 % trehalose is added as protectant before lyophilization.

Stock: 4 °C,-80 °C

Stockage commentaire: Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détail du antigène

Antigène: VEGF 165

Autre désignation: VEGF165

Sujet: VEGF, VEGFA, MVCD1, VAS, VEGFMGC70609, VPF, RP1-261G23.1, MGC70609,Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis.

Poids moléculaire: 19.2 kDa. Due to glycosylation, the protein migrates to 20-30 kDa based on Tris-Bis PAGE result.